Trial reportAnnals of oncology : official journal of the European Society for Medical Oncology2018
Clinical significance of CD73 in triple-negative breast cancer: multiplex analysis of a phase III clinical trial.
Trial report in Annals of oncology : official journal of the European Society for Medical Oncology, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 124 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
124 citing papers in PubMed, 1 synthesis or guideline pooled it, 233 citations in OpenAlex.
- Triple-Negative Breast Cancer and Predictive Markers of Response to Neoadjuvant Chemotherapy: A Systematic Review.International journal of molecular sciences · 2023Pooled it
- Durvalumab plus Paclitaxel, with or without Capivasertib or Oleclumab, in Patients with Locally Advanced/Metastatic Triple-Negative Breast Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2026Trial
- Neoadjuvant stereotactic body radiation therapy with durvalumab and oleclumab in ERNature medicine · 2026Trial
- Continuous replenishment of the dysfunctional CD8 T cell axis is associated with response to chemoimmunotherapy in advanced breast cancer.Cell reports. Medicine · 2025Trial
- Paclitaxel plus carboplatin and durvalumab with or without oleclumab for women with previously untreated locally advanced or metastatic triple-negative breast cancer: the randomized SYNERGY phase I/II trial.Nature communications · 2023Trial
- AMP hydrolysis reduction in blood plasma of breast cancer elderly patients after different treatments.Molecular and cellular biochemistry · 2021Trial
- Safety, tolerability, and pharmacology of AB928, a novel dual adenosine receptor antagonist, in a randomized, phase 1 study in healthy volunteers.Investigational new drugs · 2019Trial
- Endogenous metabolite signaling orchestrates tumor immune evasion.Cell insight · 2026Review
- Breast Cancer Milieu Maneuvers Cancer-Associated Macrophages to Synergize Neoplastic Repertoires.Cancers · 2026Review
- Descriptive study of stromal expression of CD73 in ductal carcinoma in situ of the breast.Discover oncology · 2026Article
- Article
- Epithelial-mesenchymal plasticity and immunosuppression in canine carcinomas reveals cross-species upregulation of CD109.Communications biology · 2026Article
- The CD73-adenosine axis in melanoma: from multidimensional regulation to precision immunotherapy.Frontiers in immunology · 2026Review
- Latest advances in nanodrug delivery systems for modulating the immune microenvironment in triple-negative breast cancer.Frontiers in immunology · 2026Review
- Synergistic Inhibition of Angiogenesis and Tumor Progression by CD73 Inhibitor and Menstrual Blood Stem Cell-Derived Exosomes via miR-422a Upregulation in HER2-Positive Breast Cancer.Cancer management and research · 2026Article
- Society for Immunotherapy of Cancer: Standards for Reporting of Multiplex Immunohistochemistry/Immunofluorescence Assays (STORMI).Journal for immunotherapy of cancer · 2025Article
- Breast cancer patients present pro-tumor biomarkers related to purinergic signaling and oxidative stress.Purinergic signalling · 2025Article
- CD39 and CD73: biological functions, diseases and therapy.Molecular biomedicine · 2025Review
- CD39 and CD73 Expression in Breast Cancer: CD73 as a Favorable Prognostic Factor in HER2-Positive Tumors.Journal of breast cancer · 2025Article
- UNC93B1: a novel immune-related prognostic biomarker in breast cancer.Discover oncology · 2025Article
64 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
16 authors at 5 institutions in 5 countries.
Funding
Abstract
Background: CD73 is an ecto-enzyme that promotes tumor immune escape through the production of immunosuppressive extracellular adenosine in the tumor microenvironment. Several CD73 inhibitors and adenosine receptor antagonists are being evaluated in phase I clinical trials. Patients and methods: Full-face sections from formalin-fixed paraffin-embedded primary breast tumors from 122 samples of triple-negative breast cancer (TNBC) from the BIG 02-98 adjuvant phase III clinical trial were included in our analysis. Using multiplex immunofluorescence and image analysis, we assessed CD73 protein expression on tumor cells, tumor-infiltrating leukocytes and stromal cells. We investigated the associations between CD73 protein expression with disease-free survival (DFS), overall survival (OS) and the extent of tumor immune infiltration. Results: Our results demonstrated that high levels of CD73 expression on epithelial tumor cells were significantly associated with reduced DFS, OS and negatively correlated with tumor immune infiltration (Spearman's R= -0.50, P < 0.0001). Patients with high levels of CD73 and low levels of tumor-infiltrating leukocytes had the worse clinical outcome. Conclusions: Taken together, our study provides further support that CD73 expression is associated with a poor prognosis and reduced anti-tumor immunity in human TNBC and that targeting CD73 could be a promising strategy to reprogram the tumor microenvironment in this BC subtype.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.